Polycystic Ovary Syndrome Renamed to PMOS in Landmark Global Shift
Medical authorities officially discarded the name Polycystic Ovary Syndrome (PCOS). Following a 14-year international consultation process the condition will now be known as Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The previous terminology was heavily criticised for being clinically misleading. It suggested the presence of ovarian cysts was the primary health issue when patients with the condition do not actually develop abnormal cysts. This medical inaccuracy has been blamed for decades of delayed diagnoses, limited research funding and poor clinical understanding of the illness.
The new PMOS classification accurately reflects the systemic nature of a disease that currently affects 170 mln women globally. It causes severe hormonal and metabolic disruption. Symptoms extend far beyond the ovaries to impact weight management, cardiovascular health, mental wellbeing and fertility.
The policy shift was published in The Lancet. Professor Helena Teede of Monash University spearheaded the initiative alongside international advocacy groups including the Endocrine Society, the AE-PCOS Society and the UK charity Verity. The final decision was reached after analysing 22,000 survey responses from medical professionals and patients across 50 different organisations.
For patient advocates the name change is a crucial step towards better healthcare. Rachel Morman serves as the chair of Verity. She noted that shifting the focus to the metabolic and hormonal realities of the condition will validate patient experiences and force the broader medical community to treat PMOS as a chronic systemic issue rather than a simple gynaecological anomaly.
The healthcare sector has a three-year window to implement the changes. A global education programme targeting medical professionals will run until 2028 to integrate the PMOS terminology into all diagnostic manuals and clinical guidelines.
